Table 3.

Interactions between selected variants in SEC14L2, trial vitamin E supplementation, and baseline α-tocopherol intake in relation to prostate cancer risk in the ATBC Study

			All cases		Advanced cases
Genotype	Exposure	Controls (no.)	No.	OR* (95% CI)	No.	OR* (95% CI)
	Trial vitamin E supplementation
IVS11+931A>G
AA	No	318	394	1.0	96	1.0
	Yes	274	294	0.86 (0.69−1.08)	75	0.91 (0.64−1.28)
AG+GG	No	126	129	1.0	34	1.0
	Yes	98	144	1.44 (1.01−2.05)	39	1.47 (0.86−2.49)
P interaction				0.02		0.14
IVS11−896A>T
TT	No	132	192	1.0	43	1.0
	Yes	147	137	0.64 (0.46−0.88)	25	0.52 (0.30−0.90)
AT+AA	No	310	331	1.0	89	1.0
	Yes	235	303	1.21 (0.96−1.52)	86	1.30 (0.92−1.83)
P interaction				0.002		0.007
	Baseline α-tocopherol intake, mg/d
IVS11+931A>G
AA	<8	156	192	1.0	52	1.0
	8−10.7	153	192	0.89 (0.60−1.32)	53	0.83 (0.45−1.53)
	>10.7	166	190	1.01 (0.50−2.02)	40	0.50 (0.17−1.51)
AG+GG	<8	64	63	1.0	13	1.0
	8−10.7	68	85	1.35 (0.71−2.56)	23	3.32 (1.17−9.43)
	>10.7	53	74	1.31 (0.46−3.77)	21	3.09 (0.48−20.00)
P interaction				0.15		0.007
IVS11+1032C>T
CC	<8	172	183	1.0	40	1.0
	8−10.7	165	203	1.22 (0.82−1.80)	57	2.22 (1.18−4.19)
	>10.7	156	203	1.76 (0.89−3.46)	52	1.87 (0.61−5.69)
CT+TT	<8	48	72	1.0	25	1.0
	8−10.7	56	74	0.58 (0.31−1.11)	19	0.28 (0.10−0.80)
	>10.7	63	61	0.30 (0.10−0.93)	9	0.13 (0.02−0.88)
P interaction				0.14		0.008

^*All unconditional logistic regression models adjusted for age and trial intervention assignment. Dietary models additionally adjusted for education, weight, and daily dietary intakes of fat, polyunsaturated fatty acids, vitamin C, lycopene, and total energy.